Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex

Biological Psychiatry

Volumn 39, Issue 2, 1996, Pages 82-91

  Gabriel, Steven M ^a   Davidson, Michael ^b   Haroutunian, Vahram ^b   Powchik, Peter ^b   Bierer, Linda M ^b   Purohit, Dushyant P ^b   Perl, Daniel P ^b   Davis, Kenneth L ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Alzheimer's disease; Cholecystokinin; Corticotropin releasing hormone; Gamma aminobutyric acid; Neuropeptide Y; Schizophrenia; Somatostatin; Vasoactive intestinal polypeptide

Indexed keywords

4 AMINOBUTYRIC ACID; CHOLECYSTOKININ; CORTICOTROPIN RELEASING FACTOR; NEUROPEPTIDE; SOMATOSTATIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030049514     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00066-6     Document Type: Article

References (75)

1. Akbarian S, Bunney WE Jr, Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones EG (1993): Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50:169-177.
2. Alhainen K, Sirvio J, Helkala EL, Reinikainen K, Riekkinen P (1991): Somatostatin and cognitive functions in Alzheimer's disease - the relationship of cerebrospinal fluid somatostatin increase with clinical response to tetrahydroaminoacridine. Neurosci Lett 130:46-48.
3. Allen JM, Ferrier IN, Roberts GW, Cross AJ, Adrian TE, Crow TJ, and Bloom SR (1984): Elevation of neuropeptide Y (NPY) in substantia innominata in Alzheimer's type dementia. J Neurol Sci 64:325-331.
4. Arai H, Moroji T, Kosaka K (1984): Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer-type dementia. Neurosci Lett 52:73-78.
5. Arnold SE, Franz BR, Trojanowski JQ (1993): Lack of neuropathological findings in elderly patients with schizophrenia and dementia. Soc Neurosci 18:340.10(Abstr).
6. Beal MF, Clevens RA, Mazurek MF (1988): Somatostatin and neuropeptide Y immunoreactivity in Parkinson's disease dementia with Alzheimer's changes. Synapse 2:463-467.
7. Beal MF, Growdon JH, Mazurek MF, Martin JB (1986a): CSF somatostatin-like immunoreactivity in dementia. Neurology 36:294-297.
8. Beal MF, Mazurek MF, Black PM, Martin JB (1985): Human cerebrospinal fluid somatostatin in neurologic disease. J Neurol Sci 71:91-104.
9. Beal MF, Mazurek MF, Chattha GK, Svendsen CN, Bird ED, Martin JB (1986b): Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer's disease. Ann Neurol 20:282-288.
10. Beal MF, Mazurek MF, Lorenz LJ, Chattha GK, Ellison DW, Martin JB (1986c): An examination of neuropeptide Y postmortem stability in an animal model simulating human autopsy conditions. Neurosci Lett 64:69-74.
11. Beal MF, Svendsen CN, Bird ED, Martin JB (1987): Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia. Neurochem Pathol 6:169-176.
12. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991): Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001.
13. Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP (1992): Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12:924-929.
14. Bissette G, Reynolds GP, Kilts CD, Widerlov E, Nemeroff CB (1985): Corticotropin-releasing factor-like immunoreactivity in senile dementia of the Alzheimer type. Reduced cortical and striatal concentrations. JAMA 254:3067-3069.
15. Carpenter WT Jr, Buchanan RW, Kirkpatrick B, Tamminga C, Wood F (1993): Strong inference, theory testing, and the neuroanatomy of schizophrenia. Arch Gen Psychiatry 50: 825-831.
16. Chan Palay V (1987): Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/ silver intensification on vibratome sections: Coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia. J Comp Neurol 260:201-223.
17. Chan Palay V, Jentsch B, Lang W, Asan HE (1990): Distribution of neuropeptide Y, C-terminal flanking peptide of NPY and galanin and coexistence with catacholamine in the locus coeruleus of normal human, Alzheimer's dementia and Parkinson's disease brains. Dementia 1:18-31.
18. Chan Palay V, Lang W, Allen YS, Haesler U, Polak JM (1985): Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer's-type dementia. J Comp Neurol 238:390-400.
19. Chronwall BM, Chase TN, O'Donohue TL (1984): Coexistence of neuropeptide Y and somatostatin in rat and human cortical and rat hypothalamic neurons. Neurosci Lett 52:213-217.
20. Crystal HA, Davies P (1982): Cortical substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. J Neurochem 38:1781-1784.
21. Davies CA, Morroll DR, Prinja D, Mann DM, Gibbs A (1990): A quantitative assessment of somatostatin-like and neuropeptide Y-like immunostained cells in the frontal and temporal cortex of patients with Alzheimer's disease. J Neurol Sci 96:59-73.
22. Davies P, Katzman R, Terry RD (1980): Reduced somatostatinlike immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa. Nature 288: 279-280.
23. Dawbarn D, Rossor MN, Mountjoy CQ, Roth M, Emson PC (1986): Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in senile dementia of Alzheimer type. Neurosci Lett 70:154-159.
24. de Lima AD, Morrison JH (1989): Ultrastructural analysis of somatostatin-immunoreactive neurons and synapses in the temporal and occipital cortex of the macaque monkey. J Comp Neurol 283:212-227.
25. Dennison-Cavanagh ME, Papadopoulos G, Parnavelas JG (1993): The emergence of the cortical GABAergic neuron: with particular reference to some peptidergic subpopulations. J Neurocytol 22:805-814.
26. De Souza EB, Whitehouse PJ, Kuhar MJ, Price DL, Vale WW (1986): Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature 319:593-595.
27. Eckenstein F, Baughman RW (1984): Two types of cholinergic innervation in cortex, one co-localized with vasoactive intestinal polypeptide. Nature 309:153-155.
28. Emson PC, Rossor MN, Hunt SP, Marley PD, Clement-Jones V, Rehfeld JF, Fahrenkrug J (1981): Distribution and post mortem stability of substance P, metenkephalin, VIP and cholecystokinin in normal human brain and in Huntington's disease. In Rose CR (ed), Metabolic Disorders of the Central Nervous System. London: Pitman, pp 312-321.
29. Ferrante RJ, Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JB (1985): Selective sparing of a class of striatal neurons in Huntington's disease. Science 230:561-563.
30. Ferrier IN, Cross AJ, Johnson JA, Roberts GW, Crow TJ, Corsellis JA, Lee YC, O'Shaughnessy D, Adrian TE, McGregor GP (1983): Neuropeptides in Alzheimer type dementia. J Neurol Sci 62:159-170.
31. Foley P, Hughes PD, Bradford HF, Ghatei MA, Khandanian N, Bloom SR (1992): The presence of neuropeptides in GABAergic and cholinergic rat cerebrocortical synaptosome sub-populations. Neuropeptides 23:67-72.
32. Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S (1991): Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83:273-277.
33. Gabriel SM, Bierer LM, Davidson M, Purohit DP, Perl DP, Haroutunian V (1994): Galanin-like immunoreactivity is increased in the postmortem cerebral cortex from patients with Alzheimer's disease. J Neurochem 62:1516-1523.
34. Gabriel SM, Bierer LM, Harotunian V, Purohit DP, Perl DP, Davis KL (1993): Widespread deficits in somatostatin but not neuropeptide Y concentrations in Alzheimer's disease cerebral cortex. Neurosci Lett 155:116-120.
35. Caspar P, Duyckaerts C, Febvret A, Benoit R, Beck B, Berger B (1989): Subpopulations of somatostatin 28-immunoreactive neurons display different vulnerability in senile dementia of the Alzheimer type. Brain Res 19;490:1-13.
36. Haroutunian V, Davidson M, Kanof PD, Perl DP, Powchik P, Losonczy M, McCrystal J, Purohit DP, Bierer LM, Davis KL (1993): Cortical cholinergic neuronal markers in schizophrenia. Schizophr Res (In press).
37. Hope BT, Michael GJ, Knigge KM, Vincent SR (1991): Neuronal NADPH diaphorase is a nitric oxide synthase. Proc Natl Acad Sci USA 88:2811-2814.
38. Hornung JP, De Tribolet N, Tork I (1992): Morphology and distribution of neuropeptide-containing neurons in human cerebral cortex. Neuroscience 51:363-375.
39. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982): A new clinical scale for the staging of dementia. Br J Psychiatry 140:566-572.
40. Hyman BT, Marzloff K, Wenniger JJ, Dawson TM, Bredt DS, Snyder SH (1992): Relative sparing of nitric oxide synthase-containing neurons in the hippocampal formation in Alzheimer's disease. Ann Neurol 32:818-820.
41. Kaneko T, Nakaya Y, Mizuno N (1992): Paucity of glutaminase-immunoreactive nonpyramidal neurons in the rat cerebral cortex. J Comp Neurol 322:181-190.
42. Kelley M, Kowall N (1989): Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer's disease. Brain Res 501:392-396.
43. Khachaturian ZS (1985): Diagnosis of Alzheimer's disease. Arch Neurol 42:1097-1105.
44. Kowall NW, Beal MF (1988): Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: Normal anatomy and alterations in Alzheimer's disease. Ann Neurol 23:105-114.
45. Lieberman JA, Koreen AR (1993): Neurochemistry and neuroendocrinology of schizophrenia: A selective review. Schizophr Bull 19:371-429.
46. Lowry OH, Rorebrough NJ, Farr AL, Randall RJ (1951): Protein measurement with folin reagent. J Biol Chem 193:265-272.
47. Mann DM, Yates PO, Marcyniuk B (1984): Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 10:185-207.
48. Mazurek MF, Beal MF (1991): Cholecystokinin and somatostatin in Alzheimer's disease postmortem cerebral cortex. Neurology 41:716-719.
49. Mirra SS, Heyman A, McKeel D, Sumi SM, Grain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991): The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486.
50. Miyake M, Iguchi K, Okamura H, Fukui K, Nakajima T, Chihara K, Ibata Y, Yanaihara N (1990): Effect of haloperidol on immunoreactive neuropeptide Y in rat cerebral cortex and basal ganglia. Brain Res Bull 25:263-269.
51. Nair NP, Lal S, Bloom DM (1985): Cholecystokinin peptides, dopamine and schizophrenia - a review. Prog Neuropsychopharmacol Biol Psychiatry 9:515-524.
52. Nakamura S, Vincent SR (1986): Somatostatin-and neuropeptide Y-immunoreactive neurons in the neocortex in senile dementia of Alzheimer's type. Brain Res 370:11-20.
53. Nemeroff CB, Youngblood WW, Manberg PJ, Prange AJ Jr, Kizer JS (1983): Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science 221:972-975.
54. Ong WY, Garey LJ (1991): Distribution of GABA and neuropeptides in the human cerebral cortex. Anat Embryol (Berl) 183:397-413.
55. Perez-Oso E, Lopez-Ruiz MP, Arilla E (1990): Effect of haloperidol withdrawal on somatostatin level and binding in rat brain. Biosci Rep 10:15-22.
56. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH (1978): Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 2:1457-1459.
57. Perry RH, Dockray GJ, Dimaline R, Perry EK, Blessed G, Tomlinson BE (1981): Neuropeptides in Alzheimer's disease, depression and schizophrenia. A post mortem analysis of vasoactive intestinal peptide and cholecystokinin in cerebral cortex. J Neurol Sci 51:465-472.
58. Powchik P, Davidson M, Nemeroff CB, Haroutunian V, Purohit D, Losonczy M, Bissette G, Perl D, Ghanbari H, Miller B (1993): Alzheimer's-disease-related protein in geriatric schizophrenic patients with cognitive impairment. Am J Psychiatry 150:1726-1727.
59. Purohit DP, Davidson M, Perl DP, Powchik P, Haroutunian VH, Bierer LM, McCrystal J, Losonczy M, Davis KL (1993): Severe cognitive impairment in elderly schizophrenic patients: A clinicopathological study. Biol Psychiatry 33:255-260.
60. Reinikainen KJ, Koponen H, Jolkkonen J, Riekkinen PJ (1990): Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment. Psychiatry Res 33:307-312.
61. Roberts GW, Ferner IN, Lee Y, Crow TJ, Johnstone EC, Owens DG, Bacarese Hamilton AJ, McGregor G, O'Shaughnessey D, Polak JM (1983): Peptides, the limbic lobe and schizophrenia. Brain Res 288:199-211.
62. Rogers JH (1992): Immunohistochemical markers in rat cortex: Co-localization of calretinin and calbindin-D28k with neuropeptides and GABA [published erratum appears in Brain Res 1992 598(1-2):357]. Brain Res 587:147-157.
63. Rogers JH (1992): Immunohistochemical markers in rat cortex: Co-localization of calretinin and calbindin-D28k with neuropeptides and GABA [published erratum appears in Brain Res 1992 598(1-2):357]. Brain Res 587:147-157.
64. Rossor MN, Fahrenkrug J, Emson PC, Mountjoy CQ, Iversen LL, Roth M (1980): Reduced cortical choline acetyltransferase activity in senile dementia of the Alzheimer's type is not accompanied by changes in vasocative interstinal polypeptide. Brain Res 201:249-253.
65. Rossor MN, Rehfeld JF, Emson PC, Mountjoy CQ, Roth M, Iversen LL (1981): Normal cortical concentration of cholecystokinin-like immunoreactivity with reduced choline acetyltransferase activity in senile dementia of Alzheimer type. Life Sci 29:405-410.
66. Sawchenko PE, Swanson LW, Vale WW (1984): Co-expression of corticotropin-releasing factor and vasopressin immunoreactivity in parvocellular neurosecretory neurons of the adrenalectomized rat. Proc Natl Acad Sci USA 81:1883-1887.
67. Senut MC, Menetrey D, Lamour Y (1989): Cholinergic and peptidergic projections from the medial septum and the nucleus of the diagonal band of Broca to dorsal hippocampus, cingulate cortex and olfactory bulb: A combined wheatgerm agglutinin-apohorseradish peroxidase-gold immunohistochemical study. Neuroscience 30:385-403.
68. Seroogy KB, Dangaran K, Lim S, Haycock JW, Fallon JH (1989): Ventral mesencephalic neurons containing both cholecystokinin-and tyrosine hydroxylase-like immunoreactivities project to forebrain regions. J Comp Neurol 279:397-414.
69. Tamminga CA, Foster NL, Fedio P, Bird ED, Chase TN (1987): Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology 37:161-165.
70. Uddman R, Edvinsson L (1989): Neuropeptides in the cerebral circulation. Cerebrovasc Brain Metab Rev 1:230-252.
71. Unger JW, Lange W (1992): NADPH-diaphorase-positive cell populations in the human amygdala and temporal cortex: Neuroanatomy, peptidergic characteristics and aspects of aging and Alzheimer's disease. Acta Neuropathol (Berl) 83:636-646.
72. Vincent SR, Johansson O, Hokfelt T, Skirboll L, Eide RP, Terenius L, Kimmel J, Goldstein M (1983): NADPH-diaphorase: a selective histochemical marker for striatal neurons containing both somatostatin-and avian pancreatic polypeptide (APP)-like immunoreactivities. J Comp Neurol 217:252-263.
73. White P, Hiley CR, Googhardt MJ, Carrasco LH, Keet JP, Williams IEI, Bowen DM (1977): Neocortical cholinergic neurons in elderly people. Lancet 1:668-670.
74. Widerlov E, Gottfries CG, Lindstrom L, Ekman R (1988): Brain and neuropeptide alterations in schizophrenia. Neurochem Int 13 (suppl. 1):66.
75. Zech M, Roberts GW, Bogerts B, Crow TJ, Polak JM (1986): Neuropeptides in the amygdala of controls, schizophrenics and patients suffering from Huntington's chorea: An immunohistochemical study. Acta Neuropathol (Berl) 71:259-266.